Prentiss Smith & Co. Inc. Has $124,000 Position in Core Laboratories NV (CLB)
Prentiss Smith & Co. Inc. continued to hold its stake in shares of Core Laboratories NV (NYSE:CLB) during the second quarter, Holdings Channel reports. The firm owned 1,000 shares of the company’s stock at the end of the second quarter. Prentiss Smith & Co. Inc.’s holdings in Core Laboratories NV were worth $124,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. MU Investments Co. Ltd. acquired a new stake in shares of Core Laboratories NV during the second quarter worth about $115,000. CIBC World Markets Inc. acquired a new stake in shares of Core Laboratories NV during the second quarter worth about $205,000. Creative Planning boosted its stake in shares of Core Laboratories NV by 19.8% in the second quarter. Creative Planning now owns 1,814 shares of the company’s stock worth $225,000 after buying an additional 300 shares during the last quarter. Dynamic Advisors Solutions LLC boosted its stake in shares of Core Laboratories NV by 5.6% in the second quarter. Dynamic Advisors Solutions LLC now owns 2,010 shares of the company’s stock worth $249,000 after buying an additional 106 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Core Laboratories NV during the first quarter worth about $233,000.
Shares of Core Laboratories NV (NYSE:CLB) traded up 0.71% during trading on Wednesday, hitting $111.87. 585,873 shares of the stock traded hands. Core Laboratories NV has a 12 month low of $84.50 and a 12 month high of $135.49. The firm’s 50-day moving average price is $111.66 and its 200-day moving average price is $117.58. The stock has a market cap of $4.93 billion, a PE ratio of 59.35 and a beta of 1.45.
Core Laboratories NV (NYSE:CLB) last announced its quarterly earnings results on Wednesday, July 20th. The company reported $0.35 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.35. The company had revenue of $148.10 million for the quarter, compared to the consensus estimate of $146.37 million. Core Laboratories NV had a net margin of 11.81% and a return on equity of 344.55%. Core Laboratories NV’s revenue for the quarter was down 27.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.81 EPS. Analysts anticipate that Core Laboratories NV will post $1.55 EPS for the current year.
A number of brokerages have issued reports on CLB. DA Davidson began coverage on shares of Core Laboratories NV in a report on Wednesday. They set a “buy” rating on the stock. Citigroup Inc. reduced their price target on shares of Core Laboratories NV from $123.00 to $118.00 and set a “neutral” rating for the company in a research report on Monday, July 25th. KLR Group restated a “buy” rating and set a $180.00 price target (up from $166.00) on shares of Core Laboratories NV in a research report on Monday, June 13th. Zacks Investment Research lowered shares of Core Laboratories NV from a “buy” rating to a “hold” rating in a research report on Monday, September 26th. Finally, Credit Suisse Group AG began coverage on shares of Core Laboratories NV in a research report on Thursday, September 1st. They set a “neutral” rating and a $115.00 price target for the company. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the company. Core Laboratories NV currently has an average rating of “Hold” and an average price target of $120.47.
About Core Laboratories NV
Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.
Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories NV (NYSE:CLB).
Receive News & Ratings for Core Laboratories NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories NV and related companies with MarketBeat.com's FREE daily email newsletter.